A
Artiva Biotherapeutics, Inc. (ARTV)
NGM – Real Time Price. Currency in USD
10.63
+0.03 (0.28%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
10.63
+0.03 (0.28%)
At close: May 12, 2026, 4:00 PM EDT
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. David Moriarty Ph.D. | Senior VP of Clinical Operations |
| Dr. Fred Aslan M.D. | President, CEO & Director |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development |
| Dr. Nicholas Veomett Ph.D. | Vice President of Corporate Development |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor |
| Mr. Andrew Cronauer | VP, General Counsel & Corporate Secretary |
| Mr. Benjamin Dewees | Senior Vice President of Regulatory Affairs |
| Mr. Christopher P. Horan | Chief Technical Operations Officer |
| Mr. Thad Huston C.M.A. | CFO and Principal Financial & Accounting Officer |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 10-Q | artv-20260331.htm |
| 2026-04-30 | 10-K/A | artv-20251231.htm |
| 2026-03-10 | S-8 | artv-20260310.htm |
| 2026-03-10 | 8-K | artv-20260310.htm |
| 2026-02-24 | 8-K | artv-20250128.htm |
| 2026-02-19 | 8-K | artv-20250128.htm |
| 2025-12-12 | 8-K | artv-20251210.htm |
| 2025-11-12 | 8-K | artv-20251112.htm |
| 2025-11-12 | 10-Q | artv-20250930.htm |
| 2025-08-13 | CORRESP | filename1.htm |